Renal Cancer
Development and validation of a CT-based nomogram for preoperative prediction of clear cell renal cell carcinoma grades.
February 1, 2021
A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol.
January 29, 2021
A lncRNA TCL6-miRNA-155 interaction regulates the Src-Akt-EMT network to mediate kidney cancer progression and metastasis.
January 29, 2021
Prognostic Value of Plasma hPG80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma.
January 29, 2021
Radiomics to better characterize small renal masses.
January 28, 2021
Establishment of a Risk Signature Based on m6A RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell Carcinoma.
January 27, 2021
Potential diagnostic and prognostic value and regulatory relationship of long noncoding RNA CCAT1 and miR-130a-3p in clear cell renal cell carcinoma.
January 27, 2021
First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Diagnostic Imaging Product in the United States
January 25, 2021
ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma.
January 25, 2021
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.
January 25, 2021
Dana-Farber Research Supports FDA Approval for Combination of Nivolumab and Cabozantinib in Advanced Kidney Cancer
January 23, 2021
Cabozantinib Receives U.S. FDA Approval as a First-Line Treatment in Combination with Nivolumab for Advanced Renal Cell Carcinoma
January 22, 2021